Filing search / Inhibrx Biosciences, Inc. / "Sustainability"

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

24 May 24

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

4:08pm

of people globally, while putting sustainability and social responsibility at the center of its ambitions. Cautionary Statement Regarding Forward

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

8 May 24

Other Events

4:42pm

globally, while putting sustainability and social responsibility at the center of its ambitions. Cautionary Statement Regarding Forward-Looking

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of its ambitions

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

19 Sep 23

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

4:03pm

and observations of FDA discussions, statements and beliefs regarding the current standard of care for AAT and GvHD and the sustainability of current plasma

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

30 May 23

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

9:03am

and observations of FDA discussions, statements and beliefs regarding the current standard of care for AAT and the sustainability of current plasma

8-K

EX-99.1

dz3qr6b360tc095z5

26 Apr 23

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

9:01am

8-K

EX-99.2

xy3bp

4 Oct 22

Entry into a Material Definitive Agreement

8:02am

8-K

EX-99.1

dwkvfhyr 7vvu

4 Oct 22

Entry into a Material Definitive Agreement

8:02am

8-K

EX-99.1

jdy17n3r

10 Aug 22

Regulation FD Disclosure

4:06pm

8-K

EX-99.1

0rfet8

30 Jun 22

Regulation FD Disclosure

9:01am

8-K

EX-99.2

87ewqb0m9p1d5s0a4bn

16 May 22

Regulation FD Disclosure

9:03am

8-K

EX-99.1

ze6a57oanvazoda

16 May 22

Regulation FD Disclosure

9:03am

8-K

EX-99.1

ll6 qkjiwb

4 Apr 22

Regulation FD Disclosure

4:06pm

8-K

EX-99.2

ieayinnadeqv8z2sf8a

4 Jan 22

Regulation FD Disclosure

4:41pm

8-K

EX-99.1

8pb6 ytmxra

12 Oct 21

Regulation FD Disclosure

7:50am

8-K

EX-99.2

na4lq

12 Oct 21

Regulation FD Disclosure

7:50am

8-K

EX-99.2

qmbig

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.2

dg2fdwtunmvybp

12 Mar 21

Results of Operations and Financial Condition

8:55am

8-K

EX-99.2

bw5a0m59e0q0

5 Jan 21

Inhibrx Announces Phase 1 Dose Escalation Results of

12:00am

8-K

EX-99.2

4jprjhb28ai u17

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am